Cytogen, Inc.

Equities

A217330

KR7217330000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-28 EDT			5-day change	1st Jan Change
9,950 ^KRW	-0.90%		-1.97%	-26.41%

03-20	Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI
03-18	Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	CI

Well Marker Bio Co., Ltd. announced that it has received KRW 18 billion in funding from a group of investors

July 07, 2019

Well Marker Bio Co., Ltd. announced that it has received KRW 18,000,000,000 in a round of funding on July 8, 2019. The transaction included participation from Cytogen, Inc. (KOSDAQ:A217330), HB Investment, Inc., NH Investment & Securities Co., Ltd. (KOSE:A005940), Suntree Investment Co., Ltd., Brick Investment Partners LLC, Orbit Partners Limited, and existing investor Mirae Asset Venture Investment Co., Ltd. (KOSDAQ:A100790).

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	NH INVESTMENT & SECURITIES CO., LTD.	12,190 KRW	-0.33%	-3.18%	3.06B
	MIRAE ASSET VENTURE INVESTMENT CO., LTD.	5,750 KRW	-1.03%	-0.86%	223M

Latest news about Cytogen, Inc.

Cytogen, Inc. announced that it has received KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	03-19	CI
Cytogen, Inc. announced that it expects to receive KRW 9.8 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and other investors	03-17	CI
Cytogen, Inc. announced that it has received KRW 55.49999 billion in funding from CanDx Holdings Limited	12-27	CI
Cytogen, Inc. announced that it expects to receive KRW 99.999821616 billion in funding from Candx Holdings Limited	12-27	CI
Candx Holdings Limited agreed to acquire a 31.96% stake in Cytogen, Inc. from Jeon Byung Hee and others for KRW 110 billion	12-18	CI
Cytogen, Inc. announces tranche update	23-10-26	CI
Cytogen Raising KRW10 Billion to Finance Operations	23-09-27	MT
Cytogen, Inc. announced that it expects to receive KRW 69.99999 billion in funding from Excelsior Capital Korea Limited	23-09-25	CI
Cytogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-17	CI
Cytogen, Inc.(KOSDAQ:A217330) added to S&P Global BMI Index	21-09-20	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	21-05-20	CI
TSD Life Sciences Co.,Ltd. announced that it has received KRW 2.9999853 billion in funding from Cytogen, Inc.	21-05-20	CI
Cytogen, Inc. announced that it has received KRW 30 billion in funding	21-05-19	CI
Cytogen, Inc. announced that it expects to receive KRW 30 billion in funding	21-05-16	CI
TSD Life Sciences Co.,Ltd. announced that it expects to receive KRW 2.9999853 billion in funding from Cytogen, Inc.	21-05-16	CI
Cytogen, Inc. announced that it has received KRW 10 billion in funding	20-09-24	CI
Cytogen, Inc. announced that it expects to receive KRW 10 billion in funding	20-09-03	CI
Well Marker Bio Co., Ltd. announced that it has received KRW 18 billion in funding from a group of investors	19-07-07	CI
Cytogen, Inc. has completed an IPO in the amount of KRW 20.4 billion.	18-11-21	CI
Cytogen, Inc. has filed an IPO.	18-02-20	CI
Cytogen, Inc. has withdrawn its IPO.	18-02-19	CI
Cytogen, Inc. has filed an IPO.	15-10-08	CI

Chart Cytogen, Inc.

Duration

Period

More charts

Company Profile

Cytogen Inc is a Korea-based company mainly engaged in the provision of liquid biopsy application services. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The Company distributes its products within the domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
CYTOGEN, INC.	-26.41%	163M
EXACT SCIENCES CORPORATION	-38.74%	8.27B
IOVANCE BIOTHERAPEUTICS, INC.	+12.61%	2.6B
BGI GENOMICS CO., LTD.	-18.81%	2.04B
VERACYTE, INC.	-22.90%	1.59B
MARAVAI LIFESCIENCES HOLDINGS, INC.	+35.42%	1.19B
SEEGENE, INC.	-7.86%	710M
CAREDX, INC	+9.17%	701M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-28.37%	528M
CURIOX BIOSYSTEMS CO., LTD	-8.35%	270M

Bio Diagnostics & Testing